Subchronic intravenous toxicity studies with γ-cyclodextrin in rats

Regulatory Toxicology and Pharmacology

Volumn 27, Issue 2, 1998, Pages 189-198

  Donaubauer, H H ^a   Fuchs, H ^a   Langer, K H ^a   Bar A ^b  

^a Hoechst Marion Roussel D   (Germany)

^b Bioresco AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA CYCLODEXTRIN; HEMOGLOBIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER EPITHELIUM; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG TOXICITY; ERYTHROCYTE COUNT; HEMATOCRIT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN WEIGHT; THROMBOCYTE COUNT; UREA BLOOD LEVEL;

ANIMALIA;

EID: 0031847883     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1998.1224     Document Type: Article

References (46)

1. Anderson W. R., Brewster M. E., Simpkins J. W., Bodor N. Tissue distribution of radiolabelled 2-hydroxypropyl-β-cyclodextrin in the rat. Pharm. Res. 7:1990;226.
2. Arimori K., Uekama K. Effects of β- and γ-cyclodextrins on the pharmacokinetic behavior of prednisolone after intravenous and intramuscular administrations to rabbits. J. Pharmacobio-Dyn. 10:1987;390-395.
3. Arimori K., Sakai A., Otagiri M., Uekama K. Improvement in biopharmaceutics of prednisolone by β- and γ-cyclodextrins. J. Inclusion Phenomena. 1:1984;387-394.
4. Brewster M. E., Estes K. S., Bodor N. An intravenous toxicity study of 2-hydroxypropyl-β-cyclodextrin, a useful drug solubilizer, in rats and monkeys. Int. J. Pharm. 59:1990;231-243.
5. Cabral Marques H. M. Structure and properties of cyclodextrins. Inclusion complex formation. Rev. Port. Farm. 44:1994;77-83.
6. Carpenter T. O., Gerloczy A., Pitha J. Safety of parenteral hydroxypropyl β-cyclodextrin. J. Pharm. Sci. 84:1995;222-225.
7. Coussement W., Van Cauteren H., Vandenberghe J., Vanparys P., Teuns G., Lampo A., Marsboom R. Toxicological profile of hydroxypropyl β-cyclodextrin (HP β-CD) in laboratory animals. Minutes 5th International Symposium on Cyclodextrins. 1990;Editions de Santé Paris. p. 522-524.
8. 14. Regul. Toxicol. Pharmacol. 1998.
9. Duchêne D., Wouessidjewe D. The current state of β-cyclodextrin in pharmaceutics. Acta Pharm. Technol. 36:1990;1-6.
10. Felix K., Janz S., Pitha J., Williams J. A., Mushinski E. B., Bornkamm G. W., Potter M. Cytotoxicity and membrane damagein vitro. Curr. Top. Microbiol. Immunol. 210:1996;93-99.
11. Fillastre J. P., Mignon F., Sraer J. D., Morel-Maroger L., Richet G. Insuffisance rénale aiguë reversible après traitement prolongé par le dextran. La Presse Méd. 75:1967;2535-2538.
12. Frank D. W., Gray J. E., Weaver R. N. Cyclodextrin nehprosis in the rat. Am. J. Pathol. 83:1976;367-374.
13. Frijlink H. W., Eissens A. C., Hefting N. R., Poelstra K., Lerk C. F., Meijer D. K. F. The effect of parenterally administered cyclodextrins on cholesterol levels in the rat. Pharm. Res. 8:1991;9-16.
14. Frömming K., Szejtli J. Cyclodextrins in Pharmacy. 1994;Kluwer Acad. Dordrecht.
15. Hiasa Y., Ohshima M., Kitahori Y., Yuasa T., Fujita T., Iwata C., Miyashiro A., Konishi N. Histochemical studies of β-cyclodextrin nephrosis in rats. J. Nara Med. Assoc. 32:1981;316-326.
16. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6:1979;65-70.
17. Irie T., Otagiri M., Sunada M., Uekama K., Ohtani Y., Yamada Y., Sugiyama Y. Cyclodextrin-induced hemolysis and shape changes of human erythrocytesin vitro. J. Pharmacobio-Dyn. 5:1982;741-744.
18. Irie T., Fukunaga K., Garwood M. K., Carpenter T. O., Pitha J., Pitha J. Hydroxypropylcyclodextrins in parenteral use. II. Effects on transport and disposition of lipids in rabbit and humans. J. Pharm. Sci. 81:1992;524-528.
19. Irie T., Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86:1997;147-163.
20. Jones S. P., Grant D. J. W., Hadgraft J., Parr G. Cyclodextrins in the pharmaceutical sciences. Part II. Pharmaceutical, biopharmaceutical, biological and analytical aspects, and applications of cyclodextrin and its inclusion compounds. Acta Pharm. Technol. 30:1984;263-277.
21. Kief H., Engelbart K. Reabsorptive Vacuolisation der gewundenen Nierenhauptstücke (sog. osmotische Nephrose). Frankfurter Z. Path. 75:1966;53-65.
22. Leroy-Lechat F., Wouessidjewe D., Andreux J. P., Puisieux F., Duchêne D. Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives. Int. J. Pharm. 101:1994;97-103.
23. Lina B. A. R., Bär A. Subchronic oral toxicity studies with γ-cyclodextrin in rats. Regul. Toxicol. Pharmacol. 1998.
24. Matsuda K., Mera Y., Segawa Y., Uchida I., Yokomine A., Takagi K. Acute toxicity study of γ-cyclodextrin (γ-CD) in mice and rats. Oyo Yakuri. 26:1983;287-291.
25. Monbaliu J., van Beijsterveldt L., Meuldermans W., Szathmary S., Heykants J. Disposition of hydroxypropyl β-cyclodextrin in experimental animals. Duchêne D. Minutes 5th International Symposium on Cyclodextrins. 1990;514-517 Editions de Santé Paris.
26. Ohtani Y., Irie T., Uekama K., Fukunaga K., Pitha J. Differential effects of alpha-, beta- and gamma-cyclodextrins on human erythrocytes. Eur. J. Biochem. 186:1989;17-22.
27. Okitsu-Negishi S., Nakano I., Hosoi K., Hashira S., Abe T., Fujii R., Yoshino K. The enhancing effect of β-cyclodextrin on interleukin-1 production from peritoneal macrophages in mice. Jpn. J. Inflam. 16:1996;335-344.
28. Perrin J. H., Field F. P., Hansen D. A., Mufson R. A., Torosian G. β-Cyclodextrin as an aid to peritoneal dialysis. Renal toxicity of β-cyclodextrin in the rat. Res. Commun. Chem. Pathol. Pharmacol. 19:1978;373-376.
29. Rajewski R. A., Stella V. J. Pharmaceutical applications of cyclodextrins. 2.In vivo. J. Pharm. Sci. 85:1996;1142-1169.
30. Rajewski R. A., Traiger G., Bresnahan J., Jaberaboansari P., Stella V. J., Thompson D. O. Preliminary safety evaluation of parenterally administered sulfoalkyl ether β-cyclodextrin derivatives. J. Pharm. Sci. 84:1995;927-931.
31. Riebeek, W. M. 1990a, Determination of the acute intravenous toxicity of γ-cyclodextrin in mice.
32. Riebeek, W. M. 1990b, Determination of the acute intravenous toxicity of γ-cyclodextrin in rats.
33. Riebeek, W. M. 1990c, Determination of the acute intraperitoneal toxicity of α-cyclodextrin and γ-cyclodextrin in rats.
34. Salisbury B. G. J., Falcone D. J., Minick C. R. Insoluble low-density lipoprotein-proteoglycan complexes enhance cholesteryl ester accumulation in macrophages. Am. J. Pathol. 120:1985;6-11.
35. Schmid G. Preparation and application of γ-cyclodextrin. Duchêne D. New Trends in Cyclodextrins and Derivatives. 1991;25-54 Editions de Santé Paris.
36. Schmid G. Preparation and industrial production of cyclodextrin. Comprehensive Supramolecular Chemistry. 1996;Pergamon Press, Oxford. p. 41-56.
37. Seo H., Tsuruoka M., Hashimoto T., Fujinaga T., Otagiri M., Uekama K. Enhancement of oral bioavailability of spironolactone by β- and γ-cyclodextrin complexations. Chem. Pharm. Bull. 31:1983;286-291.
38. Serfozo J., Tóth-Jakab A. Effects of β-cyclodextrin on the epithelial cells of the proximal tubules in rabbit kidney. Acta Biol. Debrecina. 19:1983/1984;87-112.
39. Shibuya K., Tajima M., Yamate J., Ihara M., Kudow S. Influence of cholesterol administration and aging on the development of pulmonary foam cells in F344 rats. Jpn. J. Vet. Sci. 51:1989;1017-1024.
40. Stella V. J., Rajewski R. A. Cyclodextrins: Their future in drug formulation and delivery. Pharm. Res. 14:1997;556-567.
41. Tabata S., Ozono S., Yamaguchi H., Kitagawa H., Uemura H., Matsuki H., Samma S., Hirao Y., Okajima E. Induction of nephrosis by β-cyclodextrin in beagles. J. Toxicol. Pathol. 4:1991;67-73.
42. Til H. P., Bär A. Subchronic (13-week) oral toxicity study of γ-cyclodextrin in dogs. Regul. Toxicol. Pharmacol. 1998.
43. Waalkens-Berendsen D. H., Smits-van Prooije A. E., Bär A. Embryotoxicity and teratogenicity study with γ-cyclodextrin in rabbits. Regul. Toxicol. Pharmacol. 1998a.
44. Waalkens-Berendsen D. H., Verhagen F. J. J., Bär A. Embryotoxicity and teratogenicity study with γ-cyclodextrin in rats. Regul. Toxicol. Pharmacol. 1998b.
45. WHO Food Additives. 1993;173-193.
46. WHO Food Additive. 1996;257-268.